Agilent to Acquire Proscia in $270M Deal

Agilent Technologies Inc. has entered a definitive agreement to acquire Proscia, a provider of digital pathology software for clinical and life-sciences customers, in an all-cash transaction valued at $240 million in cash at closing and up to an additional $30 million based on achieving future performance milestones.

Tapping into the Digital Pathology Market

Proscia serves as a key enabler to address emerging trends in the $5 billion Pathology market. Its software platform serves as a central operating layer for digital pathology, supporting clinical and life-sciences customers across the U.S. and Europe. By connecting slide scanners, laboratory information systems, image-analysis applications, AI tools, people, and data, Proscia’s technology enables customers to manage images, data, and workflows in one unified environment. The company serves more than 4,000 laboratories, hospitals, and clinics today as well as 16 of the top 20 pharmaceutical companies, with trailing twelve months revenue exceeding $18 million.

Agilent and Proscia entered into a multi-year distribution agreement in September 2022 to offer a comprehensive digital diagnostic-pathology system. Today’s announcement builds on Agilent’s established pathology solutions and its partnership with Proscia.

“Digital pathology is quickly becoming the foundation for pathology data generation, analysis, and application across biopharmaceutical research, clinical development, and diagnostics, and our acquisition of Proscia meaningfully expands our presence in this fast-growing market,” said Agilent President and CEO Padraig McDonnell. “The acquisition establishes an Agilent platform for scientific intelligence in tissue-based precision medicine, connecting data generation with AI-based interpretation in a workflow that supports biomarker research through routine clinical use.”

McDonnell believes that with Proscia’s platform and talented team, Agilent will be better equipped to help laboratories and biopharma customers manage and derive insights from pathology data.

David West, Co-Founder and CEO of Proscia, said, “Agilent shares our vision for advancing pathology through open, digital, and AI-enabled solutions. Together, we can accelerate innovation while continuing to provide customers with the flexibility they need across clinical and life-sciences workflows.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.